Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more
Sana Biotechnology Inc (SANA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -0.203x
Based on the latest financial reports, Sana Biotechnology Inc (SANA) has a cash flow conversion efficiency ratio of -0.203x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.64 Million) by net assets ($160.88 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sana Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sana Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sana Biotechnology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shaanxi Baoguang Vacuum Electronic Apparatus Co Ltd
SHG:600379
|
-0.071x |
|
GCH Technology Co. Ltd. A
SHG:688625
|
0.009x |
|
Grandjoy Holdings Group Co Ltd
SHE:000031
|
-0.023x |
|
Jiangxi Sanchuan Water Meter
SHE:300066
|
0.003x |
|
Mama's Creations Inc.
NASDAQ:MAMA
|
0.054x |
|
Ability Enterprise Co Ltd
TW:2374
|
-0.031x |
|
KEDE Numerical Control Co Ltd
SHG:688305
|
0.028x |
|
Lisi S.A
PINK:LSIIF
|
0.109x |
Annual Cash Flow Conversion Efficiency for Sana Biotechnology Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sana Biotechnology Inc from 2018 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $160.88 Million | $-143.83 Million | -0.894x | -0.36% |
| 2024-12-31 | $250.50 Million | $-223.15 Million | -0.891x | -1.00% |
| 2023-12-31 | $287.51 Million | $-253.58 Million | -0.882x | -51.84% |
| 2022-12-31 | $499.31 Million | $-290.05 Million | -0.581x | -68.56% |
| 2021-12-31 | $728.50 Million | $-251.05 Million | -0.345x | -205.19% |
| 2020-12-31 | $-421.18 Million | $-137.98 Million | 0.328x | -45.39% |
| 2019-12-31 | $-142.54 Million | $-85.50 Million | 0.600x | -41.38% |
| 2018-12-31 | $-13.19 Million | $-13.49 Million | 1.023x | -- |